Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zhaoke Ophthalmology Ltd. has secured marketing authorizations from China’s National Medical Products Administration for three new glaucoma drugs, expanding its comprehensive product portfolio for intraocular pressure management. With these additions, including Latanoprost, Travoprost, and Travoprost Timolol eye drops, the company aims to offer a broader selection for treating glaucoma patients in China, where the condition is highly prevalent. This development positions Zhaoke Ophthalmology to better serve the growing demand in the Chinese market.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.